Чи шкодують батьки, що шукали діагноз СДУГ для своєї дитини — чи шкодують, що не зробили цього?
Якщо ви дієте
Пройти формальну діагностику СДУГ та лікування (медикаменти + поведінкова терапія)
30%
Якщо ви не дієте
Чекати, уникати діагнозу або справлятися без формальної оцінки
40%
Відсоток тих, хто згодом шкодує про кожен вибір. Стовпчики та повний реєстр показані нижче.
Здоров’я
Остання перевірка 2026-05-10
Якість доказів 4.25/5
Восьмивимірна оцінка перевірки за
рубрикою якості
. Кожен вимір оцінений 1–5.
D1 Перевірка джерел
5/5
D2 Авторитет та незалежність джерела
5/5
D3 Точність частоти жалю
2/5
D4 Порівнянність джерел
2/5
D5 Шаблон Гіловича
5/5
D6 Якість прози
5/5
D7 Повнота застережень
5/5
D8 Якість вибірки
5/5
Середнє4.25/5
Замінні дані — для цього рішення не існує прямого дослідження жалю. Показники отримані з оцінок задоволеності та даних про бар'єри доступу, а не з питань, що безпосередньо стосувалися жалю. Дивіться застереження нижче.
Жаль за дію
Пройти формальну діагностику СДУГ та лікування (медикаменти + поведінкова терапія)
30%
~30 % батьків, які почали стимуляторну терапію, припиняють її протягом 12 місяців (припинення-як-проксі-для-жалю)
батьки дітей з СДУГ, які почали приймати ліки, переважно американські самообрані вибірки спільнот
поперечно, липень–грудень 2023; література про припинення 2014–2021
Жаль за бездіяльність
Чекати, уникати діагнозу або справлятися без формальної оцінки
40%
~40 % батьків, які відклали ліки для СДУГ, повідомляють про жаль через очікування (консервативна оцінка; 58 % — стеля поширеності затримки, не рівень жалю)
опікуни дітей з СДУГ (опитування ADDitude, N=11 013); дорослі з пізнім діагнозом СДУГ (лонгітюдні та якісні дослідження)
поперечне опитування 2023; лонгітюдні якісні дослідження 2015–2025
% шкодує про цей вибір
Пройти формальну діагностику СДУГ та лікування (медикаменти + поведінкова терапія)Чекати, уникати діагнозу або справлятися без формальної оцінки
30%40%
inaction dominates — Бездіяльність переважає — більшість шкодує, що не діяла.
Пов’язані рішення
Семантично близькі рішення — та сама сфера, інші компроміси.
Пропустити, відстрочити або вибірково відмовитися від дитячих щеплень (без MMR, без DTaP, альтернативний графік або повна відмова)Дотримуватися рекомендованого календаря імунізації CDC/AAP для дітей (MMR, DTaP, поліомієліт, Hib, гепатит B, вітряна віспа тощо за графіком)
In the ADDitude 2023 Treatment Scorecard survey of 11,013 caregivers and adults with ADHD, only 42% of parents opt to medicate their children in the months after a diagnosis — meaning 58% delay, largely out of fear of side effects. Respondents describe regret about that delay (“I wish I had been diagnosed and treated sooner,” one wrote), but 58% measures delay prevalence, not regret prevalence: the report does not quantify what fraction of delayers regretted waiting, so 58% is an upper bound rather than a regret rate. A conservative central estimate of 40% is used here. The picture from adults diagnosed late in life reinforces the inaction direction: a 2025 Scientific Reports study of 28 women with late-diagnosed ADHD found that all participants reported negative consequences of delayed diagnosis on quality of life and mental health, and zero regretted receiving the diagnosis once it finally came. The longitudinal outcomes literature explains why: a follow-up cohort study (Journal of Abnormal Child Psychology) found young adults diagnosed with childhood ADHD were 11 times more likely to not enroll in any post-secondary education versus a four-year college compared to non-ADHD peers, and a separate population-level study found 32.3% of those with combined-type ADHD drop out of high school — more than double the 15% rate among peers without psychiatric disorders (Breslau et al., Journal of Psychiatric Research, N=29,662).
The case for caution is real and not negligible. Side effects are common: appetite suppression is the most frequent by far, affecting 61% of children taking any stimulant, followed by sleep disruption and emotional volatility. On average, families try 2.75 different medications before settling on one that works. A large population-based study (Brikell et al. 2024, Lancet Psychiatry, 1,229,972 new users across nine jurisdictions) found that 65% of children remained on ADHD medication one year after initiation — meaning roughly 35% discontinue within the first 12 months. This discontinuation rate, largely driven by side effects and perceived inadequate effectiveness, is used here as the action-side proxy for regret or ambivalence (~30%, conservatively). The landmark MTA Study (1999), which randomized 579 children ages 7–9 to medication alone, behavioral therapy alone, combined treatment, or community care, found that medication management — alone or combined — was superior to behavioral treatment alone for core ADHD symptoms at 14 months. Yet the MTA’s longer follow-up at 6–8 years showed that the initial treatment group advantages largely converged, complicating the simple “medicate early and outcomes improve” narrative.
The Relative Age Effect adds a specific caution to early diagnosis. Children born in the month before a school enrollment cutoff are approximately 34% more likely to receive an ADHD diagnosis than those born just after the cutoff (Layton et al. 2018, NEJM, n=407,846, RR≈1.34), a finding confirmed by a 2024 meta-analysis of 32 studies with a pooled relative risk of 1.38 (European Child and Adolescent Psychiatry). This suggests that developmental immaturity is being systematically misclassified as ADHD in the youngest classroom quintile, concentrating action-side regret among families whose child was younger-for-grade. The directional finding — that inaction regret substantially exceeds action regret — is consistent with Gilovich and Medvec’s temporal asymmetry framework, which predicts that roads not taken generate more lasting regret than roads taken. Both sides of this decision carry genuine cost; neither regret rate is trivial.
Джерела: дія
Реєстр тверджень
Кожне число нижче — це те, що повідомило джерело, з дослівною цитатою, на яку ми спиралися, та тим, як ми дійшли до нашої цифри. Натисніть на посилання, щоб перевірити самостійно.
1/4 джерел незалежно перевірено дослівно за вказаним джерелом
[1]ADDitude Magazine — Special Report: ADHD Treatments Scorecard from ADDitude Readers
Авторитетне довідкове видання
Appetite suppression was the most common stimulant side effect by far, affecting 61% of children taking any stimulant; parents on average try 2.75 different medications before finding one that works; less than half (42%) of parents opt to medicate their children in the months after a diagnosis, largely due to fear of side effects
Витяг
“"Appetite suppression being the most common by far; it impacted 61% of children taking any stimulant. On average, children try 2.75 different medications and adults try 2.56 prescriptions before finding one that works for them. Less than half (42%) of parents opt to medicate their children in the months after a diagnosis, largely due to the fear of real or perceived side effects like appetite suppression or sleep disruption."
”
Дані джерела:
2024-01-01
Дата звернення
2026-05-10
Розрахунок
ADDitude editorial team survey of 11,013 opt-in newsletter subscribers (978,871 invited), data collected July 30–December 4, 2023. The survey is opt-in from an ADHD-positive community and therefore not nationally representative — it selects for families already engaged with ADHD management. Provides the 61% appetite-suppression figure (the most common stimulant side effect), which establishes the clinical burden of the action side. Action-side regret rate is not taken from this source; see the Brikell et al. 2024 Lancet Psychiatry persistence study for the quantitative basis.
[2]Academic Pediatrics / PMC — Parent Perspectives on the Decision to Initiate Medication Treatment of Attention-Deficit/Hyperactivity Disorder
Рецензована публікація
Parents reported conflicting expectancies about treatment risks and benefits, significant family pressures to avoid medication, guilt and concern that their children required medication, and distorted ideas about treatment risks
Витяг
“"Theory-based analyses revealed conflicting expectancies about treatment risks and benefits, significant family pressures to avoid medication, guilt and concern that their children required medication, and distorted ideas about treatment risks. Complex patterns of parent adherence to medication regimens were identified, as well as preferences for psychiatrists who were diagnostically expert, gave psychoeducation using multiple modalities, and used a chronic illness metaphor to explain ADHD."
”
Дані джерела:
2012-05-01
Дата звернення
2026-05-10
Розрахунок
Qualitative focus-group study of parents of children with ADHD who received a stimulant treatment recommendation. Establishes that guilt, stigma concerns, and medication ambivalence are prevalent among parents who proceed with diagnosis and treatment — providing the qualitative framing for the action-side regret estimate. This study does not supply a numeric regret rate; the Brikell et al. 2024 Lancet Psychiatry persistence study provides the quantitative basis for the ~30% figure.
[3]The Lancet Psychiatry — ADHD medication discontinuation and persistence across the lifespan: a retrospective observational study using population-based databases
Перевірено
Рецензована публікація
Within 1 year of initiation, 65% (95% CI 60–70) of children remained on ADHD medication, meaning approximately 35% discontinued within the first year
Витяг
“"Within 1 year of initiation, 65% (95% CI 60–70) of children, 47% (43–51) of adolescents, 39% (36–42) of young adults, and 48% (44–52) of adults remained on treatment. When accounting for reinitiation of medication use, 50–60% of children and 30–40% of adolescents and adults were covered with medication throughout each of the 5 follow-up years."
”
Дані джерела:
2024-01-01
Дата звернення
2026-05-10
Перевірка
Витяг незалежно повторно отримано та дослівно підтверджено за вказаним джерелом під час нашого аудиту обґрунтованості.
Розрахунок
Brikell et al. 2024, Lancet Psychiatry 11(1):16–26 (DOI 10.1016/S2215-0366(23)00332-2; PMID 38035876), retrospective observational study of 1,229,972 new ADHD-medication users across nine jurisdictions, 2010–2020. Within 1 year of initiation 65% (95% CI 60–70) of children remained on treatment, so ~35% discontinued within the first year; this first-year discontinuation figure is used as the action-side regret proxy (rounded to 30% as a conservative central estimate, since the 65% persistence CI spans 60–70% and the opt-in ADDitude sample skews toward continued engagement). Discontinuation is described as common and clinically significant, consistent with the ADDitude finding that appetite suppression (61% of children on any stimulant) is a common side-effect driver of cessation. This replaces a prior source (PMC8093505, Lohr et al. 2021) whose excerpt had misattributed the 65%/35% one-year persistence figure — that figure originates in this Lancet Psychiatry population-based study, not in the Lohr discontinuation review.
[4]Archives of General Psychiatry — A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD
Рецензована публікація
579 children with ADHD Combined Type, aged 7 to 9.9 years, randomized to 14 months of medication management, intensive behavioral treatment, the combination, or routine community care; medication management (alone or combined) was superior to behavioral treatment alone and community care for core ADHD symptoms
Витяг
“"A group of 579 children with ADHD Combined Type, aged 7 to 9.9 years, were assigned to 14 months of medication management, intensive behavioral treatment, the combination, or routine community care."
”
Дані джерела:
1999-12-01
Дата звернення
2026-07-03
Розрахунок
MTA Cooperative Group (1999), Archives of General Psychiatry, 56(12):1073-86. PMID 10591283. The landmark 4-arm randomized trial referenced in caveats and body as context for medication efficacy; corrects a prior draft's "576 children" to the confirmed N=579. Not used in regret_rate arithmetic; cited as background on treatment efficacy that complicates (but does not resolve) the diagnose-early-vs-wait framing, especially given the longer-term (6-8 year) MTA follow-up showing initial treatment-group differences converged.
Незалежність
Landmark NIMH-funded multi-site RCT; independent of the Brikell et al. discontinuation study and the ADDitude survey.
Джерела: бездіяльність
Реєстр тверджень
Кожне число нижче — це те, що повідомило джерело, з дослівною цитатою, на яку ми спиралися, та тим, як ми дійшли до нашої цифри. Натисніть на посилання, щоб перевірити самостійно.
1/6 джерел незалежно перевірено дослівно за вказаним джерелом
[1]ADDitude Magazine — Special Report: ADHD Treatments Scorecard from ADDitude Readers
Авторитетне довідкове видання
Less than half (42%) of parents opt to medicate their children in the months after a diagnosis, so 58% delay; one respondent wrote 'I wish I had been diagnosed and treated sooner'
Витяг
“"Less than half (42%) of parents opt to medicate their children in the months after a diagnosis, largely due to the fear of real or perceived side effects like appetite suppression or sleep disruption. 'I wish I had been diagnosed and treated sooner,' wrote one survey respondent. 'The struggle is so profound and deep.'"
”
Дані джерела:
2024-01-01
Дата звернення
2026-05-10
Розрахунок
ADDitude 2023 Treatment Scorecard (N=11,013 opt-in subscribers). The survey reports that only 42% of parents medicate within the months after diagnosis, so 58% delay (100% - 42% = 58%). 0.58 is therefore the delay-prevalence ceiling, not the regret rate: it measures how many delayed, not how many of those delayers regretted it. The ADDitude report does not quantify what percentage of respondents regretted waiting — it offers only qualitative respondent testimony (e.g. "I wish I had been diagnosed and treated sooner"). We therefore cannot use 0.58 directly as an inaction-side regret rate. We adjust to 0.40 as a conservative central estimate: acknowledging that (a) not all who delayed ultimately regretted it, (b) the opt-in ADHD-aware sample almost certainly overstates population-level regret, and (c) 0.40 sits below the 0.58 delay-prevalence ceiling while remaining above the action-side 0.30 rate, consistent with the late-diagnosis regret literature (PMC12218314). 0.58 is explicitly flagged as an upper bound in the regret_display.
[2]Scientific Reports / PMC (Nature Portfolio) — Adverse experiences of women with undiagnosed ADHD and the invaluable role of diagnosis
Рецензована публікація
Participants commonly reported guilt, shame, and negative self-perception due to delayed ADHD diagnosis; none of the interviewed individuals regretted going through neuropsychiatric evaluation once they finally received it
Витяг
“"Participants commonly reported internalising criticism and described disconcertingly low self-esteem; citing guilt, shame, and negative self-perception due to delayed diagnoses. Participants found diagnosis revelatory, their lives finally making sense; citing healing, improved self-esteem, and life feeling more worth living. Many women expressed regret at the fact that they were not diagnosed and treated earlier in their lives."
”
Дані джерела:
2025-01-01
Дата звернення
2026-05-10
Розрахунок
Mixed-methods survey and qualitative study of 28 women with late-diagnosed ADHD, published in Scientific Reports 2025 (PMC12218314). All participants reported negative consequences of delayed diagnosis on quality of life and mental health; zero regretted receiving the diagnosis. This qualitative evidence provides directional support for the high inaction-side regret rate: those who lived without a diagnosis uniformly wished for earlier identification. The N=28 sample is small and female-skewed; it is used here as a directional anchor alongside the larger ADDitude survey, not as a standalone prevalence estimate.
[3]Journal of Abnormal Child Psychology / PMC — Young Adult Educational and Vocational Outcomes of Children Diagnosed with ADHD
Перевірено
Рецензована публікація
Young adults with childhood ADHD were 11 times more likely to not enroll in any school vs. 4-year college; 15% held a 4-year degree vs. 48% of controls; 0.06% held a graduate degree vs. 5.4% of controls
Витяг
“"Young adults diagnosed with ADHD are far less likely to enroll in a 4-year college and are 11 times more likely to not enroll in any school versus enrolling in a 4-year college, with 50% attending vocational or junior colleges versus 18% of the non-ADHD comparison group, 15% holding a 4-year degree compared to 48% of the control group, and 0.06% holding a graduate degree compared to 5.4% of the control group."
”
Дані джерела:
2012-11-01
Дата звернення
2026-05-10
Перевірка
Витяг незалежно повторно отримано та дослівно підтверджено за вказаним джерелом під час нашого аудиту обґрунтованості.
Розрахунок
Longitudinal follow-up study comparing children diagnosed with ADHD (recruited from a clinical treatment program) against a non-ADHD community comparison group, followed into young adulthood. This establishes an objective outcome gap between ADHD and non-ADHD young adults; the ADHD group itself was diagnosed and clinically treated in childhood, so the study does not isolate undiagnosed or untreated status as the cause of the gap. It is cited here as background on the general educational/vocational stakes of ADHD rather than as direct evidence that delay specifically (as opposed to the underlying disorder) drives the outcome gap. This study does not measure parent regret directly.
[4]Journal of Psychiatric Research / PMC — Childhood and adolescent onset psychiatric disorders, substance use, and failure to graduate high school on time
Рецензована публікація
32.3% of students with combined-type ADHD dropped out of high school, compared to 15% of those with no psychiatric disorder
Витяг
“"Of 29,662 respondents, about one third (32.3%) of students with combined-type ADHD dropped out of high school. This figure was twice that of teens with no reported mental health problems (15%) who did not graduate."
”
Дані джерела:
2011-01-01
Дата звернення
2026-05-10
Розрахунок
Breslau et al., Journal of Psychiatric Research, using National Epidemiological Survey of Alcohol and Related Conditions data (N=29,662), collected 2001–2002. Provides the 32% combined-type ADHD high school dropout statistic cited in the prose. This is a population- level association; the study does not establish that treatment would have prevented dropout, but combined-type ADHD is the subtype most commonly treated with stimulants, making this an indirect proxy for the inaction cost. Not used in rate arithmetic — cited as a causal mechanism anchor alongside the educational outcomes study.
[5]New England Journal of Medicine — Attention Deficit–Hyperactivity Disorder and Month of School Enrollment↗ 1 other entry
Рецензована публікація
Among 407,846 children, the rate of ADHD diagnosis was 34% higher among children born in August than among those born in September in states with September 1 kindergarten cutoffs (RR≈1.34)
Витяг
“"Among the 407,846 children in our database who were born between 2007 and 2009, there were 36,319 born in August and 35,353 born in September who lived in 1 of 18 states with a September 1 birthday cutoff for kindergarten enrollment. The rate of ADHD diagnosis was 34% higher among the children born in August than among those born in September."
”
Дані джерела:
2018-11-29
Дата звернення
2026-05-10
Розрахунок
Layton TJ, Barnett ML, Hicks TR, et al. N Engl J Med 2018;379:2122–2130. n=407,846 children, quasi-experimental design exploiting September 1 kindergarten enrollment cutoffs across 18 states. Establishes the Relative Age Effect (RAE) on ADHD diagnosis: being the youngest in a classroom increases diagnosis probability by ~34% (RR≈1.34). This corrects the previous "up to 1.6 times" figure in caveats prose, which is not supported by this paper. The RAE represents a documented confounder: developmental immaturity misclassified as ADHD in the youngest classroom quintile. Not used in regret rate arithmetic; cited as a diagnostic-accuracy caveat.
[6]European Child and Adolescent Psychiatry — Systematic review and meta-analysis: relative age in attention-deficit/hyperactivity disorder and autism spectrum disorder
Рецензована публікація
Meta-analysis of 32 studies found younger relative age associated with ADHD diagnosis (RR=1.38, 95% CI 1.36–1.52) and ADHD medication (RR=1.28, 95% CI 1.21–1.36)
Витяг
“"Younger relative age was associated with ADHD diagnosis and medication, with relative risks of 1.38 (1.36–1.52 95% CI) and 1.28 (1.21–1.36 95% CI) respectively. The meta-analysis included 32 studies, with 31 investigating ADHD and 2 examining ASD. Risk estimates exhibited high heterogeneity, indicating significant variability across studies."
”
Дані джерела:
2024-05-20
Дата звернення
2026-05-10
Розрахунок
2024 systematic review and meta-analysis published in European Child and Adolescent Psychiatry (PMC11868292). 32 studies included. Pooled RR for ADHD diagnosis = 1.38 (95% CI 1.36–1.52), meaning youngest-in-class children are 38% more likely to receive an ADHD diagnosis. This is the source for "pooled RR 1.38" cited in caveats. High heterogeneity limits precision; some sub-analyses reach higher values for specific subgroups, but 1.38 is the pooled central estimate. Not used in regret rate arithmetic; cited as a diagnostic-accuracy caveat alongside Layton 2018.
Застереження
Neither figure is a direct measure of regret about the diagnose-vs.-wait decision. The action-side ~30% is the 12-month stimulant discontinuation rate among children (Brikell et al. 2024, Lancet Psychiatry, population-based observational study of 1,229,972 new users; 65% of children remained on treatment within 1 year, so ~35% discontinued, rounded down to ~30% as the conservative central estimate), used here as a proxy because discontinuation is the nearest available quantitative measure of action-side regret or ambivalence. The inaction-side 40% is a conservative estimate, not a directly measured regret rate. In the ADDitude 2023 Treatment Scorecard (N=11,013), only 42% of parents medicated within the months after diagnosis, so 58% delayed; the report offers qualitative testimony of regret about waiting (e.g. one respondent: "I wish I had been diagnosed and treated sooner") but does not quantify what fraction of respondents regretted the delay. The 58% figure is the delay-prevalence ceiling (100% − 42% who medicated after diagnosis = 58% who delayed) — it measures how many delayed, not how many regretted the delay. We reduce 0.58 to 0.40 because (a) not all who delayed regretted it, (b) the ADDitude sample is opt-in from an ADHD-aware community and almost certainly overstates regret in the general population, and (c) the absence of a regret denominator makes 0.58 an explicit upper bound. The two sides draw on different constructs and populations: action-side data comes from stimulant discontinuation literature; inaction-side data conflates families who delayed medication post-diagnosis with those who never pursued diagnosis at all — these are meaningfully different decisions. The Relative Age Effect is a documented diagnostic-accuracy confounder: children born in the month before a school enrollment cutoff are approximately 34% more likely to receive an ADHD diagnosis than children born just after the cutoff (Layton et al. 2018, NEJM, n=407,846, RR≈1.34), confirmed by a 2024 meta-analysis of 32 studies with pooled relative risk 1.38 (European Child and Adolescent Psychiatry; PMC11868292). This means some proportion of diagnoses — especially in the youngest classroom quintile — may reflect developmental immaturity rather than a genuine neurodevelopmental disorder, concentrating action-side regret among families whose child was younger-for-grade. Diagnostic accuracy varies substantially by clinician, setting, and whether behavioral therapy was attempted first. US ADHD diagnosis prevalence (9–11% of children) is markedly higher than European rates (3–5%), partly reflecting different diagnostic thresholds rather than true prevalence differences. The MTA Study (1999) remains the landmark randomized trial: carefully monitored medication management was superior to behavioral treatment alone for core ADHD symptoms at 14 months; combined treatment showed consistently greater benefit across broader outcome domains. However, longer-term MTA follow-up (6–8 years) showed that initial treatment group advantages largely converged, complicating the case for aggressive early treatment. Educational outcomes for untreated or under-treated combined-type ADHD are poor: a population-level study (Breslau et al., Journal of Psychiatric Research, N=29,662) found 32.3% of combined-type ADHD students dropped out of high school, double the 15% rate in peers without psychiatric disorders; this figures in the inaction-side mechanism alongside the longitudinal vocational outcomes literature. Parents who have biological ADHD themselves face an additional layer of complexity: their own lived experience of diagnosed versus undiagnosed ADHD substantially shapes their tolerance for delay.
